Mizuho Securities raised the price target for Boston Scientific Corporation (NYSE:BSX), saying the cardiology segment is poised to deliver double-digit growth. Citing the virtual NDR group meeting, Mizuho Securities Managing Director Anthony Petrone said high-level feedback suggests that the cardiology segment is poised to maintain a “healthy” double-digit top-line growth profile for the foreseeable future supported by rapid Farapulse adoption, Watchman FLX upside from combo pulsed field ablation concomitant surgery with left atrial appendage closure (PFA and LAAC) surgery, and core CRM renaissance supported by Emblem S-ICD adoption. Related: Boston Scientific Lifts 2024 Profit Forecast On Strong Growth From Cardiovascular Devices, Stock Soars. Mizuho wrote, “Feedback supports our view that U.S. Farapulse contribution can approach our $400 million bull case scenario this year while combo PFA + LAAC surgery can drive ...